Catastrophic brain relapse in seronegative NMO after a single dose of natalizumab
Natalizumab, an effective treatment for MS, has been shown to exacerbate neuromyelitis optica (NMO) with aquaporin-4 antibodies, but whether this is the case in antibody negative NMO and atypical MS/NMO spectrum disorder overlap syndromes is unknown. We describe a patient with a relapsing optico-spi...
| Үндсэн зохиолчид: | , , , , , |
|---|---|
| Формат: | Journal article |
| Хэл сонгох: | English |
| Хэвлэсэн: |
Elsevier
2014
|
| _version_ | 1826280833737031680 |
|---|---|
| author | Kitley, J Evangelou, N Küker, W Jacob, A Leite, M Palace, J |
| author_facet | Kitley, J Evangelou, N Küker, W Jacob, A Leite, M Palace, J |
| author_sort | Kitley, J |
| collection | OXFORD |
| description | Natalizumab, an effective treatment for MS, has been shown to exacerbate neuromyelitis optica (NMO) with aquaporin-4 antibodies, but whether this is the case in antibody negative NMO and atypical MS/NMO spectrum disorder overlap syndromes is unknown. We describe a patient with a relapsing optico-spinal demyelinating syndrome, negative for aquaporin-4 antibodies, who experienced a catastrophic brain relapse shortly after a single dose of natalizumab, highlighting that MS immunomodulatory drugs may worsen demyelination in patients with seronegative NMO and atypical MS/NMO overlap syndromes even if they are aquaporin-4 antibody negative. We summarise the treatments considered safe and effective in NMO, and those with potential to exacerbate disease. © 2014 Elsevier B.V. |
| first_indexed | 2024-03-07T00:19:40Z |
| format | Journal article |
| id | oxford-uuid:7c1aaa09-d788-408b-9d33-b893f6dffa6a |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-07T00:19:40Z |
| publishDate | 2014 |
| publisher | Elsevier |
| record_format | dspace |
| spelling | oxford-uuid:7c1aaa09-d788-408b-9d33-b893f6dffa6a2022-03-26T20:54:51ZCatastrophic brain relapse in seronegative NMO after a single dose of natalizumabJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:7c1aaa09-d788-408b-9d33-b893f6dffa6aEnglishSymplectic Elements at OxfordElsevier2014Kitley, JEvangelou, NKüker, WJacob, ALeite, MPalace, JNatalizumab, an effective treatment for MS, has been shown to exacerbate neuromyelitis optica (NMO) with aquaporin-4 antibodies, but whether this is the case in antibody negative NMO and atypical MS/NMO spectrum disorder overlap syndromes is unknown. We describe a patient with a relapsing optico-spinal demyelinating syndrome, negative for aquaporin-4 antibodies, who experienced a catastrophic brain relapse shortly after a single dose of natalizumab, highlighting that MS immunomodulatory drugs may worsen demyelination in patients with seronegative NMO and atypical MS/NMO overlap syndromes even if they are aquaporin-4 antibody negative. We summarise the treatments considered safe and effective in NMO, and those with potential to exacerbate disease. © 2014 Elsevier B.V. |
| spellingShingle | Kitley, J Evangelou, N Küker, W Jacob, A Leite, M Palace, J Catastrophic brain relapse in seronegative NMO after a single dose of natalizumab |
| title | Catastrophic brain relapse in seronegative NMO after a single dose of natalizumab |
| title_full | Catastrophic brain relapse in seronegative NMO after a single dose of natalizumab |
| title_fullStr | Catastrophic brain relapse in seronegative NMO after a single dose of natalizumab |
| title_full_unstemmed | Catastrophic brain relapse in seronegative NMO after a single dose of natalizumab |
| title_short | Catastrophic brain relapse in seronegative NMO after a single dose of natalizumab |
| title_sort | catastrophic brain relapse in seronegative nmo after a single dose of natalizumab |
| work_keys_str_mv | AT kitleyj catastrophicbrainrelapseinseronegativenmoafterasingledoseofnatalizumab AT evangeloun catastrophicbrainrelapseinseronegativenmoafterasingledoseofnatalizumab AT kukerw catastrophicbrainrelapseinseronegativenmoafterasingledoseofnatalizumab AT jacoba catastrophicbrainrelapseinseronegativenmoafterasingledoseofnatalizumab AT leitem catastrophicbrainrelapseinseronegativenmoafterasingledoseofnatalizumab AT palacej catastrophicbrainrelapseinseronegativenmoafterasingledoseofnatalizumab |